Advanced integration for continuous manufacturing of nanocarriers
DIANT offers a scalable, continuous manufacturing system for nanocarriers utilizing a proprietary jet mixing strategy. This equipment integrates inline PAT and downstream processing, enhancing speed and consistency in nanoparticle formulation, ideal for pharmaceutical and vaccine production.
Overview
DIANT presents an advanced solution for continuous manufacturing of nanocarriers, utilizing a proprietary jet mixing strategy. This technology employs a linear, jet-in-jet design enabling seamless scalability from low to high volumes. The system boasts integrated modules such as inline Process Analytical Technology (PAT) and downstream processing, providing real-time particle size monitoring and ensuring highly consistent nanoparticle formulations. This makes DIANT's solution particularly valuable for pharmaceutical and vaccine manufacturing, enhancing the speed and repeatability of nanoparticle production.
Technical specifications
Key features:
- Proprietary jet mixing strategy: Linear, jet-in-jet design for scalable production.
- Integrated inline PAT: Real-time understanding of particle size.
- Downstream processing: Enhances speed and repeatability of formulation.
- Compatibility: Can integrate with upstream API payloads and final fill/finish systems.
- High throughput capacity: Facilitates large-scale nanoparticle production.
Technology readiness level
Currently at Technology Readiness Level 6, the DIANT system has been validated with technologies such as LNP, liposomes, and polymer carriers. The equipment has been tested under clean room conditions and is capable of formulation optimization and technology transfer. This robust platform supports nanomedicine delivery without the need for licensing or royalties, providing an ideal basis for research partnerships and commercial applications.
About DIANT
DIANT Pharma Inc. is a biopharmaceutical solutions company that specializes in continuous manufacturing technology for nanoparticles and lipid nanoparticles (LNPs). Founded in 2019, the company developed the proprietary DIANT Jet technology, a system designed to replace traditional batch processing with an integrated, closed-loop, and automated manufacturing process. This technology enables precise, inline control over particle size and characteristics while facilitating scalable production from research and development phases through to commercial manufacturing. By consolidating multiple unit operations into a single step, the platform is engineered to improve product quality, increase efficiency, and reduce cGMP manufacturing risks for nucleic acid-based therapies and other advanced treatments.
These solutions are critical for biopharmaceutical partners, CDMOs, and innovators seeking to accelerate time-to-market and improve the reliability of nanoparticle-based medicines. The company’s technology has been recognized for its potential to de-risk development, with the U.S. Food and Drug Administration acquiring a DIANT system for internal research into advanced manufacturing processes. Beyond equipment, DIANT provides extensive R&D, consulting, and formulation services, offering turnkey solutions that help clients overcome the limitations of older, batch-based manufacturing methods across pharmaceutical, nutraceutical, and cosmetic applications.
delivered to your inbox.